Scarica l'app Stockscreener
0.9674
5.15%
0.0474
Dopo l'orario di chiusura:
.97
0.0026
+0.27%
Precedente Chiudi:
$0.92
Aprire:
$0.93
Volume 24 ore:
57,603
Relative Volume:
0.71
Capitalizzazione di mercato:
$23.07M
Reddito:
-
Utile/perdita netta:
$-22.29M
Rapporto P/E:
-0.8198
EPS:
-1.18
Flusso di cassa netto:
$-17.12M
1 W Prestazione:
+3.35%
1M Prestazione:
-12.05%
6M Prestazione:
-22.61%
1 anno Prestazione:
-29.90%
Intervallo 1D:
$0.9201
$0.97
Intervallo di 1 settimana:
$0.92
$0.983
Portata 52W:
$0.8101
$1.76
Enlivex Therapeutics Ltd Stock (ENLV) Company Profile
Nome
Enlivex Therapeutics Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta ENLV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ENLV
Enlivex Therapeutics Ltd
|
0.9674 | 22.36M | 0 | -22.29M | -17.12M | -1.18 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.232 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.34 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Enlivex Therapeutics Ltd Stock (ENLV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-03-02 | Reiterato | H.C. Wainwright | Buy |
Enlivex Therapeutics Ltd Borsa (ENLV) Ultime notizie
Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Friday - Defense World
Enlivex Reports Q1 2025 Financial Results with Reduced Loss - TipRanks
Enlivex Therapeutics (NASDAQ:ENLV) Shares Down 4% – Time to Sell? - Defense World
ENLIVEX THERAPEUTICS Earnings Preview: Recent $ENLV Insider Trading, Hedge Fund Activity, and More - Nasdaq
Enlivex (ENLV) to Present Cell Therapy Advancements at Israeli B - GuruFocus
Revolutionary Cell Therapy Shows 47% Pain Reduction in Osteoarthritis: Enlivex Reveals Breakthrough Data - Stock Titan
Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers - Barchart.com
Renaissance Technologies LLC Acquires 84,203 Shares of Enlivex Therapeutics Ltd. (NASDAQ:ENLV) - Defense World
Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis - ACCESS Newswire
Enlivex stock holds Buy rating with $7 target from H.C. Wainwright - Investing.com India
Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoa - GuruFocus
Enlivex to Present Allocetra™ Insights at OARSI 2025 - TipRanks
Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress - The Manila Times
Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World ... - Bluefield Daily Telegraph
Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress - TradingView
Game-Changing Cell Therapy Helps Patients Avoid Knee Replacement: Clinical Trial Results Revealed - Stock Titan
Enlivex enrols all patients in Phase II stage of knee osteoarthritis trial - Yahoo
Enlivex Therapeutics (NASDAQ:ENLV) Given “Buy” Rating at D. Boral Capital - Defense World
Enlivex (ENLV) Completes Patient Enrollment for Phase II Allocetra Trial | ENLV Stock News - GuruFocus
Enlivex Completes Phase II Enrollment for Osteoarthritis Trial - TipRanks
Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis - The Manila Times
Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis | ENLV Stock News - GuruFocus
Enlivex Therapeutics Completes Patient Enrollment in Phase II Trial of Allocetra™ for Knee Osteoarthritis - Nasdaq
Major Milestone: 133-Patient Phase II Trial Completed for Revolutionary Knee Osteoarthritis Treatment Allocetra - Stock Titan
Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Invest In Growth? - Yahoo Finance
D. Boral Capital Reaffirms “Buy” Rating for Enlivex Therapeutics (NASDAQ:ENLV) - Defense World
Enlivex Begins Phase I Trial for TMJ Osteoarthritis Treatment - TipRanks
Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis - The Manila Times
Groundbreaking TMJ Treatment Trial Begins: Enlivex Targets Major Medical Need - Stock Titan
Enlivex Therapeutics Releases 2024 Financial Statements - TipRanks
HC Wainwright Has Negative Estimate for ENLV FY2025 Earnings - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Enlivex Therapeutics (NASDAQ:ENLV) Stock - The AM Reporter
Enlivex Therapeutics (NASDAQ:ENLV) Given New $7.00 Price Target at HC Wainwright - Defense World
Enlivex stock price target raised to $7 at H.C. Wainwright By Investing.com - Investing.com South Africa
Enlivex stock price target raised to $7 at H.C. Wainwright - Investing.com India
Enlivex Secures Chinese Patent Allowance for Osteoarthritis Treatment - TipRanks
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis - The Manila Times
Enlivex Therapeutics Secures Patent Allowance in China for Allocetra™ as Treatment for Osteoarthritis - Nasdaq
Breakthrough: Enlivex's Arthritis Drug Cuts Pain by 47%, Secures Major China Patent Win - StockTitan
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Update - Defense World
IOBT To Report Melanoma Trial Data In Q3, NPCE Eyes 15-20% Revenue Growth For 2025, DXR On Watch - RTTNews
Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis - The Manila Times
Enlivex Reports Promising Interim Results in Osteoarthritis Trial - TipRanks
Enlivex Therapeutics Announces Investor Webinar To Discuss Positive Interim Data From Phase I/Ii Allocetra(TM) Trial In Knee Osteoarthritis - Marketscreener.com
Enlivex Therapeutics Ltd. Hosts Investor Webinar to Discuss Positive Interim Data from Allocetra™ Osteoarthritis Trial - Nasdaq
Can Enlivex's Allocetra Transform Osteoarthritis Treatment? 47% Pain Reduction Reported - StockTitan
Enlivex Therapeutics (NASDAQ:ENLV) Given Buy Rating at D. Boral Capital - Defense World
Enlivex Announces Positive Interim Data From Early Stage Trial For Osteoarthritis Treatment - Nasdaq
Enlivex Reports Promising Interim Results in Knee Osteoarthritis Trial - TipRanks
Enlivex Announces Positive Interim DataStatistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis - The Manila Times
Enlivex Therapeutics Reports Positive Interim Results in Phase I/II Trial of Allocetra™ for Knee Osteoarthritis - Nasdaq
Enlivex Therapeutics Ltd Azioni (ENLV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
2.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):